Streetbeat News

Products Services

ALLO

Allogene Therapeutics, Inc. (NASDAQ:ALLO) and Arbor Biotechnologies announced a global licensing agreement for Arbor's CRISPR gene-editing technology to be used in Allogene's AlloCAR T platform for autoimmune disease treatment. This collaboration aims to develop effective and accessible CAR T therapies, with the first AlloCAR T investigational product expected to enter Phase 1 clinical trials in early 2025.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:57 pm

AAPL

META

Mark Zuckerberg, CEO of Meta Platforms Inc. (META), has countered claims by tech analyst Benedict Evans that Apple Inc.'s (AAPL) Vision Pro is similar to Meta's Quest lineup, emphasizing differences in product capabilities and vision. Zuckerberg highlighted the Quest's superiority in terms of weight, motion blur, and precision inputs, despite acknowledging Vision Pro's higher resolution. He also refuted the notion that VR headsets are solely for gaming, pointing out the outdated narrative and emphasizing the Quest's good resolution and other advantages.

Portfolio Pulse from Ananya Gairola

March 12, 2024 | 12:56 pm

GWRE

Guidewire Software, Inc. (GWRE) has been selected by Ascot to modernize its claims IT operations. The financial terms of the agreement were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:56 pm

BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced positive results from a Phase 2 study of VOXZOGO in children with hypochondroplasia, to be presented at the ACMG Annual Clinical Genetics Meeting. The study showed increased annualized growth velocity with no new safety concerns. Additionally, data from Phase 2 and 3 studies in achondroplasia demonstrated sustained growth improvement and quality of life benefits. BioMarin is also conducting a pivotal clinical trial program for VOXZOGO in hypochondroplasia and has ongoing extension studies in achondroplasia to fulfill post-marketing requirements.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:55 pm

PFE

Pfizer Inc (NYSE:PFE) announced positive results from a Phase 3 study of Adcetris combined with lenalidomide and rituximab for treating diffuse large B-cell lymphoma (DLBCL), showing significant improvement in overall survival compared to a placebo combination. This marks the third Phase 3 study where an Adcetris combination has shown an overall survival benefit in lymphoma treatment. The results are notable for evaluating heavily pre-treated patients. Pfizer acquired Adcetris through its $43 billion acquisition of Seagen Inc. PFE shares saw a slight decrease of 0.09% in premarket trading.

Portfolio Pulse from Vandana Singh

March 12, 2024 | 12:55 pm

NNOX

Nanox.AI's software, HealthVCF, significantly improves the detection of vertebral compression fractures (VCFs), a key risk factor for osteoporosis, by up to six times the national average in the UK's NHS hospitals. This early finding from the ADOPT study highlights the potential of AI in enhancing patient identification for osteoporosis treatment, leading to better patient outcomes and healthcare savings. The study, involving collaborations with the University of Oxford and others, will continue until February 2025. Nanox.AI has also developed an updated version of the software, HealthOST, which received FDA 510(K) clearance in April 2022.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:49 pm

QCOM

Qualcomm is reportedly on the verge of unveiling its latest flagship SoC, which is specifically designed to support generative AI, as per industry sources cited by DigiTimes.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:48 pm

GUTS

Fractyl Health's stock price has increased due to positive preclinical findings for its RJVA-001 gene therapy candidate. The company's progress in developing this therapy has attracted investor attention, leading to a rise in its shares.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:47 pm

ONON

ORCL

RGLS

Oracle (ORCL) shares rose by 14% following positive Q3 financial results. Regulus Therapeutics (RGLS) shares surged by 103% after announcing promising topline results from a Phase 1b study and a $100 million private placement. On Holding (ONON) shares fell by 18% due to disappointing Q4 financial results.

Portfolio Pulse from ryanfaloona@benzinga.com

March 12, 2024 | 12:43 pm

GUTS

Fractyl Health, Inc. (NASDAQ:GUTS) announced promising preclinical findings for RJVA-001, its first GLP-1 gene therapy candidate from the Rejuva platform, demonstrating potent and durable effects in treating obesity and type 2 diabetes compared to Semaglutide.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:40 pm